Phagocytic activity and pro-inflammatory cytokines production by the murine macrophage cell line J774A.1 stimulated by a recombinant BCG (rBCG) expressing the MSP1-C of Plasmodium falciparum

Tropical Biomedicine

Volumn 27, Issue 3, 2010, Pages 461-469

  Rapeah, S ^a   Dhaniah, M ^a   Nurul, A A ^a   Norazmi, M N ^a  

^a SCHOOL OF HEALTH SCIENCES   (Malaysia)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; MALARIA VACCINE; MEROZOITE SURFACE PROTEIN 1; RECOMBINANT PROTEIN;

ANIMAL; ARTICLE; BIOSYNTHESIS; CELL LINE; GENETICS; IMMUNOLOGY; MACROPHAGE; MACROPHAGE ACTIVATION; MOUSE; MYCOBACTERIUM BOVIS; PHAGOCYTOSIS; PLASMODIUM FALCIPARUM;

ANIMALS; CELL LINE; CYTOKINES; MACROPHAGE ACTIVATION; MACROPHAGES; MALARIA VACCINES; MEROZOITE SURFACE PROTEIN 1; MICE; MYCOBACTERIUM BOVIS; PHAGOCYTOSIS; PLASMODIUM FALCIPARUM; RECOMBINANT PROTEINS;

EID: 78650774851     PISSN: 01275720     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Alonso, P.L., Sacarlal, J., Aponte, J.J., Leach, A., Macete, E., Aide, P., Sigauque, B., Milman, J., Mandomand, I., Bassat, Q., Guinovart, C., Espasa, M., Corachan, S., Lievens, M., Navia, M.M., Dubois, M.C., Menendez, C., Dubovsky, F., Cohen, J., Thompson, R. & Ballou, W.R. (2005). Duration of protection with RTS,S/ AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial. Lancet 366(9502): 2012-2018.
2. Angulo, I. & Fresno, M. (2002). Cytokines in the pathogenesis of and protection against malaria. Clinical and Diagnostic Laboratory Immunology 9(6): 1145-1152.
3. Blackman, M.J., Heidrich, H.G., Donachie, S., McBride, J.S. & Holder, A.A. (1990). A single fragment of a malaria merozoite surface protein remains on the parasite during red cell invasion and is the target of invasion-inhibiting antibodies. Journal of Experimental Medicine 172: 379-382.
4. Bogdan, C. (2001). Nitric oxide and the immune response. Nature Immunology 2: 907-916.
5. Britton, W.J. & Palendira, U. (2003). Improving vaccine against tuberculosis. Immunology and Cell Biology 81: 34-45.
6. Elliott, S.R. & Beeson, J.G. (2008). Estimating the burden of global mortality in children aged <5 years by pathogen-specific causes. Clinical Infectious Disease 46: 1794-1795.
7. Ferreira, M.U. & Hartl, D.L. (2007). Plasmodium falciparum: Worldwide sequence diversity and evolution of the malaria vaccine candidate merozoite surface protein-2 (MSP-2). Experimental Parasitology 115: 32-40.
8. Genton, B., Al-Yaman, F., Betuela, I., Anders, R.F., Saul, A., Baea, K., Mellombo, M., Taraika, J., Brow, G.V., Pye, D., Irving, D.O., Felger, I., Beck, H.P., Smith, T.A. & Alpers, M.P. (2003). Safety and immunogenicity of a three-component blood-stage malaria vaccine (MSP1, MSP2, RESA) against Plasmodium falciparum in Papua New Guinean children. Vaccine 22: 30-41.
9. Gopinath, V.K., Musa, M., Samsudin, A.R., Lalitha, P. & Sosroseno, W. (2006). Role of nitric oxide in hydroxyapati-induced phagocytosis by murine macrophage cell line (RAW264.7). Archives of Oral Biology 51: 339-344.
10. Guerra, C.A., Gikandi, P.W., Tatem, A.J., Noor, A.M., Smith, D.L., Hay, S.I. & Snow, R.W. (2008). The limits and intensity of Plasmodium falciparum transmission: Implications for malaria control and elimination worldwide. PLoS Medicine 5(2): e38.
11. Hall, N., Karras, M., Raine, J.D., Carlton, J.M., Kooij, T.W., Berriman, M., Florens, L., Janssen, C.S., Pain, A., Christophides, G.K., James, K., Rutherford, K., Harris, B., Harris, D., Churcher, C., Quail, M.A., Ormond, D., Doggett, J., Trueman, H.E., Mendoza, J., Bidwell, S.L., Rajandream, M.A., Carucci, D.J., Yates, J.R, 3rd, Kafatos, F.C., Janse, C.J., Barrell, B., Turner, C.M., Waters, A.P. & Sinden, R.E. (2005). A comprehensive survey of the Plasmodium life cycle by genomic, transcriptomic, and proteomic analyses. Science 307: 82-86.
12. Harris, P.K., Yeoh, S., Dluzewski, A.R., O'Donnell, R.A., Withers-Martinez, C., Hackett, F., Bannister, L.H., Mitchell, G.H. & Blackman, M.J. (2005). Molecular identification of a malaria merozoite surface sheddase. PLoS Pathogens 1(3): e29.
13. Hirunpetcharat, C., Tian, J.H., Kaslow, D.C., van Rooijen, N., Kumar, S., Berzofsky, J.A., Miller, L.H. & Good. M.F. (1997). Complete protective immunity induced in mice by immunization with the 19- kilodalton carboxyl-terminal fragment of the merozoite surface protein-1 (MSP1[19]) of Plasmodium yoelii expressed in Saccharomyces cerevisiae: correlation of protection with antigenspecific antibody titer, but not with effector CD4+ T cells. The Journal of Immunology 159: 3400-3411.
14. Hoffman, S.L., Crutcher, J.M., Puri, S.K., Ansari, A.A., Villinger, F., Franke, E.D., Singh, P.P., Finkelman, F., Gately, M.K., Dutta, G.P. & Sedegah, M. (1997). Sterile protection of monkeys against malaria after administration of interleukin-12. Nature Medicine 3(1): 80-83.
15. Jacobs, P., Radzioch, D. & Stevenson, M.M. (1996). A Th1-associated increase in tumor necrosis factor alpha expression in the spleen correlates with resistance to blood-stage malaria in mice. Infection and Immunity 64: 535-541.
16. John, C.C., O'Donnell, R.A., Sumba, P.O., Moormann, A.M., de Koning-Ward, T.F., King, C.L., Kazura, J.W. & Crabb, B.S. (2004). Evidence that invasioninhibitory antibodies specific for the 19- kDa fragment of merozoite surface protein-1 (MSP-119) can play a protective role against blood-stage Plasmodium falciparum infection in individuals in a malaria endemic area of Africa. Journal of Immunology 173:666-672.
17. Kern, P., Hemmer, C.J., Van Damme, J., Gruss, H.J. & Dietrich, M. (1989). Elevated tumor necrosis factor alpha and interleukin-6 serum levels as markers for complicated Plasmodium falciparum malaria. American Journal of Medicine 87: 139-143.
18. King, C.L., Malhotra, I., Wamachi, A., Kioko, J., Mungai, P., Abdel Wahab, S., Davy Koech, D., Zimmerman, P., Ouma, J. & Kazura, W. J. (2002). Acquired immune responses to Plasmodium falciparum merozoite surface protein-1 in the human fetus. The Journal of Immunology 168(1): 356-364.
19. Lee, J.Y., Kim, J.Y., Lee, Y.G., Byeon, S.E., Kim, B.H., Rhee, M.H., Lee, A., Kwon, M., Hong, S. & Cho, J.Y. (2007). In vitro immunoregulatory effects of Korean mistletoe lectin on functional activation of monocytic and macrophage-like cells. Biological Pharmaceutical Bulletin 30(11): 2043-2051.
20. Mshana, R.N., Boulandi, J., Mshana, N.M., Mayombo, J. & Mendome, G. (1991). Cytokines in the pathogenesis of malaria: Levels of IL-1, IL-4, IL-6, TNF-α, and IFN-γ in plasma of healthy individuals and malaria patients in a holoendemic area. Journal of Clinical and Laboratory Immunology 34: 131-139.
21. Norazmi, M.N., Zainuddin, Z.F., Suppian, R. & Dale, J.W. (1999). The use of assembly polymerase chain reaction for cloning of a malarial epitope into Mycobacterium smegmatis -importance of overcoming codon bias. Biotechnology Techniques 13: 485-489.
22. O'Donnell, R.A., Saul, A., Cowman, A. & Crabb, B.S. (2000). Functional conservation of the malaria vaccine antigen MSP-119 across distantly related Plasmodium species. Nature Medicine 6:91-95.
23. O'Donnell, R.A., de Koning-Ward, T.F., Burt, R.A., Bockarie, M., Reeder, J.C., Cowman, A.F. & Crabb, B.S. (2001). Antibodies against merozoite surface protein (MSP)-1(19) are a major component of the invasion-inhibitory response in individuals immune to malaria. Journal of Experimental Medicine 193(12): 1403-1412.
24. Perera, K.L., Handunnetti, S.M., Holm, I., Longacre, S. & Mendis, K. (1998). Baculovirus merozoite surface protein 1 C-terminal recombinant antigens are highly protective in a natural primate model for human Plasmodium vivax malaria. Infection and Immunity 66: 1500-1506.
25. Prinzis, S., Chatterjee, D. & Brennan, P.J. (1993). Structure and antigenicity of lipoarabinomannan from Mycobacterium bovis BCG. Journal of General Microbiology 139: 2649-2658.
26. Rocket, K.A., Awburn, M.M., Cowden, W.B. & Clark, I.A. (1991). Killing of Plasmodium falciparum in vitro by nitric oxide derivatives. Infection and Immunity 59: 3280-3283.
27. Sacarlal, J., Aponte, J.J., Aide, P., Mandomando, I., Bassat, Q., Guinovart, C., Leach, A., Milman, J., Macete, E., Espasa, M., Ofori-Anyinam, O., Thonnard, J., Corachan, S., Dubois, M.C., Lievens, M., Dubovsky, F., Ballou, W.R., Cohen, J. & Alonso, P.L. (2008). Safety of the RTS,S/AS02A malaria vaccine in Mozambican children during a Phase IIb trial. Vaccine 26(2): 174-84.
28. Sam, H. & Stevenson, M.M. (1999). Early IL- 12 p70, but not p40, production by splenic macrophages correlates with host resistance to blood-stage Plasmodium chabaudi AS malaria. Clinical and Experimental Immunology 117(2): 343-349.
29. Sedegah, M., Finkelman, F. & Hoffman, S.L. (1994). Interleukin 12 induction of interferon gamma-dependent protection against malaria. Proceeding of the National Academy of Sciences of the United State of America 91: 10700-10702.
30. Serghides, I., Smith, T.G., Patel, S.N. & Kain, K.C. (2003). CD36 and malaria: friends or foes? Trends in Parasitology 19: 461-469.
31. Stevenson, M.M. & Riely, E.M. (2004). Innate immunity to malaria. Nature Reviews Immunology 4:169-180.
32. Stevenson, M.M., Tam, M.F., Wolf, S.F. & Sher, A. (1995). IL-12-induced protection against blood-stage Plasmodium chabaudi AS requires IFN-γ and TNF-α and occurs via a nitric oxide-dependent mechanism. The Journal of Immunology 155: 2545-2556.
33. Taylor-Robinson, A.W. & Looker, M. (1998). Sensitivity of malaria parasites to nitric oxide at low oxygen tensions. The Lancet 351: 1630-1630.
34. Wan Omar, A., Roslaini, A.M., Ngah, Z.U., Azahari, A.A., Zahedi, M. & Baharudin, O. (2007). A recombinant 19-kDa Plasmodium berghei merozoite surface protein 1 formulated with alum induces protective immune response in mice. Tropical Biomedicine 24(1): 119-126.
35. Wipasa, J., Elliott, S., Xu, H. & Good, M.F. (2002). Immunity to asexual blood stage malaria and vaccine approches. Immunology and Cell Biology 80: 401-441.
36. Yazdani, S.S., Mukherjee, P., Chauhan, V.S. & Chitnis, C.E. (2006). Immune responses to asexual blood-stages of malaria parasites. Current Molecular Medicine 6: 187-203.